Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Jean‐Michel Molina, Douglas Ward, Indira Brar, Anthony Mills, Hans‐Jürgen Stellbrink, Luís F. López‐Cortés, Peter Ruane, Daniel Podzamczer, Cynthia Brinson, Joseph M. Custodio,

The Lancet HIV · 2018 · 192 citations · 14 references

Concepts

References

14